Symptomatic HCM with Left Ventricular Outflow Tract Gradient ≥50 mmHg: What to Do When Verapamil or Diltiazem Did Not Improve Symptoms
This protocol addresses obstructive hypertrophic cardiomyopathy in patients who remain symptomatic despite a prior course of rate-limiting therapy, with a resting or provoked left ventricular outflow tract (LVOT) gradient persisting at or above the threshold for further intervention.
Clinical Scenario
Symptoms attributable to left ventricular outflow tract obstruction (LVOTO), with a resting or provoked LVOT gradient ≥50 mmHg. LVOTO is defined by convention as a peak instantaneous Doppler LVOT gradient of ≥30 mmHg; the threshold for escalated treatment is generally considered to be ≥50 mmHg.
Previous Treatment — Failure Condition
Prior therapy
Verapamil or diltiazem, titrated to maximum tolerated dose.
Goal not achieved
Improvement of symptoms.
When symptom improvement is not attained with verapamil or diltiazem at maximum tolerated dose, this next-line protocol applies.
Next-Step Treatment Approach (Partial)
The approach involves adding a second agent to existing background rate-limiting therapy — with the choice guided by tolerability and cardiac imaging parameters. Titration is performed to the maximum tolerated dose, with ongoing echocardiographic surveillance required for one of the options. The complete agent selection, sequencing, and monitoring protocol is available via the link below.
Treatment Goal
Improvement of symptoms
References
DOI: 10.1093/eurheartj/ehad194
By convention, LVOTO is defined as a peak instantaneous Doppler LV outflow tract gradient of ≥30 mmHg, but the threshold for invasive treatment is usually considered to be ≥50 mmHg.
Non-vasodilating beta-blockers, titrated to maximum tolerated dose, are recommended as first-line therapy to improve symptoms in patients with resting or provoked LVOTO.
Disopyramide, titrated to maximum tolerated dose, is recommended in addition to a beta-blocker (or, if this is not possible, with verapamil or diltiazem) to improve symptoms in patients with resting or provoked LVOTO.
Cardiac myosin ATPase inhibitor (mavacamten), titrated to maximum tolerated dose with echocardiographic surveillance of LVEF, should be considered in addition to a beta-blocker (or, if this is not possible, with verapamil or diltiazem) to improve symptoms in adult patients with resting or provoked LVOTO.
View source ↗